Bacterial Sexually Transmitted Infection Screening Rates by Symptomatic Status Among Men Who Have Sex With Men in the United States: A Hierarchical Bayesian Analysis.


Journal

Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 26 7 2018
medline: 26 2 2020
entrez: 26 7 2018
Statut: ppublish

Résumé

Prevention of bacterial sexually transmitted infections (STIs) among men who have sex with men (MSM) requires timely disease detection, but this is complicated by asymptomatic infection. We estimated screening/testing rates by symptomatic status to evaluate adherence to Centers for Disease Control and Prevention STI screening guidelines. In a cross-sectional study of 2572 US MSM aged 15 to 65 years in 2017 to 2018, we measured the reported number of asymptomatic STI screens in the past 2 years versus tests prompted by disease symptoms. Using negative binominal regression within a hierarchical Bayesian framework, we estimated yearly rates of asymptomatic screening and symptomatic testing by geographic, demographic, and behavioral factors. Human immunodeficiency virus (HIV) status was most strongly associated with all testing/screening frequency (incidence rate ratio [IRR], 1.72; 95% credible interval [Crl], 1.49, 1.97). The HIV-uninfected MSM had 0.14 (95% credible interval [CrI], 0.12-0.17) symptomatic tests and 0.88 (95% CrI, 0.77-1.01) asymptomatic screens per year. The HIV-infected MSM had 0.25 (95% CrI, 0.18-0.35) symptomatic tests and 1.53 (95% CrI, 1.24-1.88) asymptomatic screens per year. Rates of asymptomatic screening were higher among black compared with white MSM (IRR, 1.41; 95% CrI, 1.15-1.73), but weakly associated with number of past-year sexual partners (IRR, 1.01; 95% CrI, 1.00-1.01). Overall, 85% to 90% of diagnostic events were asymptomatic screens. Self-reported rates of STI screening were close to Centers for Disease Control and Prevention's recommended overall annual screening frequency, but with gaps defined by demographics and behavioral risk. Targeted screening efforts may be indicated specifically for younger MSM and those with multiple partners.

Sections du résumé

BACKGROUND
Prevention of bacterial sexually transmitted infections (STIs) among men who have sex with men (MSM) requires timely disease detection, but this is complicated by asymptomatic infection. We estimated screening/testing rates by symptomatic status to evaluate adherence to Centers for Disease Control and Prevention STI screening guidelines.
METHODS
In a cross-sectional study of 2572 US MSM aged 15 to 65 years in 2017 to 2018, we measured the reported number of asymptomatic STI screens in the past 2 years versus tests prompted by disease symptoms. Using negative binominal regression within a hierarchical Bayesian framework, we estimated yearly rates of asymptomatic screening and symptomatic testing by geographic, demographic, and behavioral factors.
RESULTS
Human immunodeficiency virus (HIV) status was most strongly associated with all testing/screening frequency (incidence rate ratio [IRR], 1.72; 95% credible interval [Crl], 1.49, 1.97). The HIV-uninfected MSM had 0.14 (95% credible interval [CrI], 0.12-0.17) symptomatic tests and 0.88 (95% CrI, 0.77-1.01) asymptomatic screens per year. The HIV-infected MSM had 0.25 (95% CrI, 0.18-0.35) symptomatic tests and 1.53 (95% CrI, 1.24-1.88) asymptomatic screens per year. Rates of asymptomatic screening were higher among black compared with white MSM (IRR, 1.41; 95% CrI, 1.15-1.73), but weakly associated with number of past-year sexual partners (IRR, 1.01; 95% CrI, 1.00-1.01). Overall, 85% to 90% of diagnostic events were asymptomatic screens.
CONCLUSIONS
Self-reported rates of STI screening were close to Centers for Disease Control and Prevention's recommended overall annual screening frequency, but with gaps defined by demographics and behavioral risk. Targeted screening efforts may be indicated specifically for younger MSM and those with multiple partners.

Identifiants

pubmed: 30044334
doi: 10.1097/OLQ.0000000000000896
pmc: PMC6292678
mid: NIHMS983990
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

25-30

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH112449
Pays : United States

Références

Sex Transm Dis. 2005 Oct;32(10 Suppl):S11-8
pubmed: 16205286
Prev Med. 2003 Apr;36(4):502-9
pubmed: 12649059
Sex Transm Infect. 2010 Oct;86(5):371-6
pubmed: 20460263
Sex Transm Dis. 2018 Jul;45(7):469-475
pubmed: 29465659
Sex Transm Dis. 2017 Nov;44(11):678-684
pubmed: 28876305
MMWR Morb Mortal Wkly Rep. 2017 Apr 07;66(13):349-354
pubmed: 28384130
AIDS Patient Care STDS. 2008 Dec;22(12):947-54
pubmed: 19072101
AIDS. 2018 Feb 20;32(4):523-530
pubmed: 29239887
Clin Infect Dis. 2005 Jul 1;41(1):67-74
pubmed: 15937765
J Acquir Immune Defic Syndr. 2012 May 1;60(1):83-90
pubmed: 22522237
J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):537-43
pubmed: 19935075
AIDS Res Hum Retroviruses. 2015 Jun;31(6):587-92
pubmed: 25719950
J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):275-9
pubmed: 26068721
MMWR Morb Mortal Wkly Rep. 2007 Jun 29;56(25):625-8
pubmed: 17597693
Clin Infect Dis. 2014 Jun;58(11):1564-70
pubmed: 24647015
Lancet HIV. 2017 Jul;4(7):e311-e320
pubmed: 28431923
J Acquir Immune Defic Syndr. 2017 Jul 1;75 Suppl 3:S363-S369
pubmed: 28604440
AIDS Behav. 2015 Oct;19(10):1860-74
pubmed: 25638038
Clin Infect Dis. 2017 Sep 1;65(5):712-718
pubmed: 28505240
Sex Transm Infect. 2017 Aug;93(5):307-308
pubmed: 28389442
Sex Transm Dis. 2014 Jul;41(7):433-9
pubmed: 24922102
PLoS One. 2014 Mar 07;9(3):e90514
pubmed: 24608176
JMIR Public Health Surveill. 2015 Apr 17;1(1):e3
pubmed: 27227126
AIDS Behav. 2014 Apr;18 Suppl 3:297-304
pubmed: 23605156
Am J Public Health. 2006 Jun;96(6):1007-19
pubmed: 16670223
Sex Transm Dis. 2018 Jan;45(1):8-13
pubmed: 29240633
MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137
pubmed: 26042815

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH